

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2007 (25.10.2007)

PCT

(10) International Publication Number
WO 2007/118647 A1

(51) International Patent Classification:

CI2N 9/04 (2006.01)

(21) International Application Number:

PCT/EP2007/003207

(22) International Filing Date: 11 April 2007 (11.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

06007779.9 13 April 2006 (13.04.2006) EP

(71) Applicant (for DE only): **ROCHE DIAGNOSTICS GMBH** [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) Applicant (for all designated States except DE, US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOENITZ-DU-LAT, Mara** [DE/DE]; Hofmairstrasse 23, 82327 Tutzing (DE). **BECK, Daniela** [DE/DE]; Poennensperchstrasse

13, 82377 Penzberg (DE). **KRATZSCH, Peter** [DE/DE]; Loisachstrasse 48, 82377 Penzberg (DE). **SCHMUCK, Rainer** [DE/DE]; Am Klosterweiher 7, 83671 Benediktbeuern (DE). **VON DER ELTZ, Herbert** [DE/DE]; In der Au 21, 82362 Weilheim (DE).

(74) Common Representative: **ROCHE DIAGNOSTICS GMBH**; c/o NASER, Werner, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: IMPROVED MUTANTS OF PYRROLOQUINOLINE QUINONE DEPENDENT SOLUBLE GLUCOSE DEHYDROGENASE

Schematic diagram of the plasmide with gene for s-GDH (pACSGDH)



(57) Abstract: The present invention discloses a mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine, wherein said mutant additionally comprises, at least one mutation for improving the stability of the mutant and one or more mutation(s) for improving the affinity of the mutant to glucose, and/or one or more mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose, and wherein position 348 correspond to the amino acid positions known from the *A. calcoaceticus*-GDH wild-type sequence. Also disclosed are genes encoding such mutant s-GDH, and different applications of these s-GDH mutants, particularly for determining the concentration of glucose in a sample.

WO 2007/118647 A1



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Improved mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase

The present invention relates to a mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine and wherein said mutant additionally comprises, at least one mutation for improving the stability of the mutant and one or more mutation(s) for improving the affinity of the mutant to hexoses, e.g. preferably glucose, and/or one or more mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose, and wherein these positions correspond to the amino acid positions known from the *A. calcoaceticus* s-GDH wild-type sequence. Also disclosed are genes encoding such mutant s-GDH, and different applications of these s-GDH mutants, particularly for determining the concentration of glucose in a sample.

Background of the Invention

The determination of blood glucose concentration is extremely important in clinical diagnosis and in the management of diabetes. Approximately 150 million people worldwide suffer from the chronic disease *diabetes mellitus*, a figure that may double by 2025 according to the WHO. Although diabetes is readily diagnosed and treated, successful long-term management requires low-cost diagnostic tools that rapidly and accurately report blood glucose concentrations. PQQ-dependent glucose dehydrogenases (EC 1.1.5.2) catalyze a reaction in which glucose is oxidized to gluconolactone. Consequently, this type of enzyme is used in measuring blood sugar. One of these tools is a diagnostic strip based on the soluble glucose dehydrogenase (s-GlucDOR, EC 1.1.5.2), a pyrroloquinoline quinone-containing enzyme originally derived from *Acinetobacter calcoaceticus*.

Quinoproteins use quinone as cofactor to oxidize alcohols, amines and aldoses to their corresponding lactones, aldehydes and aldolic acids (Duine, J.A., Energy generation and the glucose dehydrogenase pathway in *Acinetobacter*, in "The Biology of *Acinetobacter*" New York, Plenum Press (1991), pp. 295-312; Duine, J.A., Eur. J. Biochem. 200 (1991) 271-284; Davidson, V.L., in "Principles and applications of quinoproteins", the whole book, New York, Marcel Dekker (1993); Anthony, C., Biochem. J. 320 (1996) 697-711; Anthony, C. and Ghosh, M., Current

Science 72 (1997) 716-727; Anthony, C., Biochem. Soc. Trans. 26 (1998) 413-417; Anthony, C. and Ghosh, M., Prog. Biophys. Mol. Biol. 69 (1998) 1-22. Among quinoproteins, those containing the noncovalently bound cofactor 2,7,9-tricarboxy-1H-pyrrolo [2,3-f]quinoline-4,5-dione (PQQ) constitute the largest sub-group (Duine 1991, supra). All bacterial quinone glucose dehydrogenases known so far belong to this sub-group with PQQ as cofactor (Anthony and Ghosh 1997 supra; Goodwin, P.M. and Anthony, C., Adv. Microbiol. Physiol. 40 (1998) 1-80; Anthony, C., Adv. in Phot. and Resp. 15 (2004) 203-225).

Two types of PQQ-dependent glucose dehydrogenase (EC 1.1.5.2) have been characterized in bacteria: One is membrane-bound (m-GDH); the other is soluble (s-GDH). Both types do not share any significant sequence homology (Cleton-Jansen, A.M., et al., Mol. Gen. Genet. 217 (1989) 430-436; Cleton-Jansen, A.M., et al., Antonie Van Leeuwenhoek 56 (1989) 73-79; Oubrie, A., et al., Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 11787-11791. They are also different regarding both their kinetic as well as their immunological properties (Matsushita, K., et al., Bioscience Biotechnol. & Biochem. 59 (1995) 1548-1555). The m-GDHs are widespread in Gram-negative bacteria, s-GDHs, however, have been found only in the periplasmic space of *Acinetobacter* strains, like *A. calcoaceticus* (Duine, J.A., 1991a; Cleton-Jansen, A.M. et al., J. Bacteriol. 170 (1988) 2121-2125; Matsushita and Adachi, 1993) and *A. baumannii* (JP 11243949).

Through searching sequence databases, two sequences homologous to the full-length *A. calcoaceticus* s-GDH have been identified in *E.coli* K-12 and *Synechocystis* sp.. Additionally, two incomplete sequences homologous to *A. calcoaceticus* s-GDH were also found in the genome of *P. aeruginosa* and *Bordetella pertussis* (Oubrie et al. 1999 a, b, c) and *Enterobacter intermedium* (Kim, C.H. et al., Current Microbiol. 47 (2003) 457-461), respectively. The deduced amino acid sequences of these four uncharacterized proteins are closely related to *A. calcoaceticus* s-GDH with many residues in the putative active site absolutely conserved. These homologous proteins are likely to have a similar structure and to catalyze similar PQQ-dependent reactions (Oubrie et al., 1999 a, b, c; Oubrie A., Biochim. Biophys. Acta 1647 (2003) 143-151; Reddy, S., and Bruice, T.C., J. Am. Chem. Soc. 126 (2004) 2431-2438; Yamada, M. et al., Biochim. Biophys. Acta 1647 (2003) 185-192).

Bacterial s-GDHs and m-GDHs have been found to possess quite different sequences and different substrate specificity. For example, *A. calcoaceticus* contains two different PQQ-dependent glucose dehydrogenases, one designated m-GDH

which is active *in vivo*, and the other designated s-GDH for which only *in vitro* activity can be shown. Cleton-Jansen et al., 1988; 1989 a, b cloned the genes coding for the two GDH enzymes and determined the DNA sequences of both of these GDH genes. There is no obvious homology between m-GDH and s-GDH corroborating the fact that m-GDH and s-GDH represent two completely different molecules (Laurinavicius, V., et al., *Biologija* (2003) 31-34).

The gene of s-GDH from *A. calcoaceticus* has been cloned in *E. coli*. After being produced in the cell, the s-GDH is translocated through the cytoplasmic membrane into the periplasmic space (Duine, J.A., *Energy generation and the glucose dehydrogenase pathway in Acinetobacter*, in "The Biology of *Acinetobacter*", New York, Plenum Press (1991), pp. 295-312; Matsushita, K. and Adachi, O., *Bacterial quinoproteins glucose dehydrogenase and alcohol dehydrogenase*, in "Principles and applications of Quinoproteins", New York, Marcel Dekker (1993) pp. 47-63). Like the native s-GDH from *A. calcoaceticus*, recombinant s-GDH expressed in *E. coli* is a homodimer, with one PQQ molecule and three calcium ions per monomer (Dokter, P. et al., *Biochem. J.* 239 (1986) 163-167; Dokter, P. et al., *FEMS Microbiol. Lett.* 43 (1987) 195-200; Dokter, P. et al., *Biochem. J.* 254 (1988) 131-138; Olsthoorn, A.J. and Duine, J.A., *Arch. Biochem. Biophys.* 336 (1996) 42-48; Oubrie, A., et al., *J. Mol. Biol.* 289 (1999) 319-333; Oubrie, A., et al., *Proc. Natl. Acad. Sci. U.S.A* 96 (1999) 11787-11791; Oubrie, A., et al., *Embo J.* 18 (1999) 5187-5194). s-GDH oxidizes a wide range of mono- and disaccharides to the corresponding ketones which further hydrolyze to the aldonic acids, and it is also able to donate electrons to PMS (phenazine metosulfate), DCPIP (2,6-dichlorophenolindophenol), WB (Wurster's blue) and short-chain ubiquinones such as ubiquinone Q1 and ubiquinone Q2 (Matsushita, K., et al., *Biochem.* 28 (1989) 6276-6280; Matsushita, K., et al., *Antonie Van Leeuwenhoek* 56 (1989) 63-72), several artificial electron acceptors such as N-methylphenazonium methyl sulfate (Olsthoorn, A.J. and Duine, J.A., *Arch. Biochem. Biophys.* 336 (1996) 42-48; Olsthoorn, A.J. and Duine, J.A., *Biochem.* 37 (1998) 13854-13861) and electro conducting polymers (Ye, L., et al., *Anal. Chem.* 65 (1993) 238-241). In view of s-GDH's high specific activity towards glucose (Olsthoorn, A.J. and Duine, J.A., (1996) *supra*) and its broad artificial electron acceptor specificity, the enzyme is well suited for analytical applications, particularly for being used in (bio-)sensor or test strips for glucose determination in diagnostic applications (Kaufmann, N. et al., Development and evaluation of a new system for determining glucose from fresh capillary blood and heparinized blood in "Glucotrend" (1997) 1-16, Boehringer

Mannheim GmbH; Woosuck, S. et al., Sensors and Actuators B 100 (2004) 395-402).

5 Glucose oxidation can be catalyzed by at least three quite distinct groups of enzymes, i.e., by NAD/P-dependent glucose dehydrogenases, by flavoprotein glucose oxidases or by quinoprotein GDHs (Duine, J.A., Biosens. Bioelectronics 10 (1995) 17-23). A rather slow autooxidation of reduced s-GDH has been observed, demonstrating that oxygen is a very poor electron acceptor for s-GDH (Olsthoorn and Duine, 1996). s-GDH can efficiently donate electrons from the reduced quinone to mediators such as PMS, DCPIP, WB and short-chain ubiquinones such as Q1 and Q2, but it can not efficiently donate electrons directly to oxygen.

10 Traditional test strips and sensors for monitoring glucose level in blood, serum and urine e. g. from diabetic patients use glucose oxidase. The performance of the enzyme is dependent of the oxygen concentration. Glucose measurements at different altitudes with different oxygen concentrations in the air may lead to false results. The major advantage of PQQ-dependent glucose dehydrogenases is their independence from oxygen. This important feature is e.g., discussed in US 6,103,509, in which some features of membrane-bound GDH have been investigated.

20 An important contribution to the field has been the use of s-GDH together with appropriate mediators. Assay methods and test strip devices based on s-GDH are disclosed in detail in US 5,484,708. This patent also contains detailed information on the set-up of assays and the production of s-GDH-based test strips for measurement of glucose. The methods described there as well as in the cited documents are herewith included by reference.

25 Other patents or applications relating to the field and comprising specific information on various modes of applications for enzymes with glucose dehydrogenase activity are US 5,997,817; US 6,057,120; EP 0 620 283; and JP 11-243949-A.

30 A commercial system which utilizes s-GDH and an indicator that produces a color change when the reaction occurs (Kaufmann, et al., 1997, supra) is the Glucotrend® system distributed by Roche Diagnostics GmbH.

Despite the above discussed advantages for use of a PQQ dependent s-GDH, in the determination of glucose also a disadvantage has to be considered. The enzyme has

rather a broad substrate spectrum as compared to m-GDH. That is, s-GDH oxidizes not only glucose but also several other sugars including maltose, galactose, lactose, mannose, xylose and ribose (Dokter et al. 1986 a; Oubrie A., *Biochim. Biophys. Acta* 1647 (2003) 143-151). The reactivity towards sugars other than glucose may in certain cases impair the accuracy of determining blood glucose levels. In particular patients on peritoneal dialysis, treated with icodextrin (a glucose polymer) may contain in their body fluids, e.g., in blood, high levels of other sugars, especially of maltose (Wens, R., et al., *Perit. Dial. Int.* 18 (1998) 603-609).

Therefore clinical samples as e.g. obtained from diabetic patients, especially from patients with renal complications and especially from patients under dialysis may contain significant levels of other sugars, especially maltose. Glucose determinations in samples obtained from such critical patients may be impaired by maltose (Frampton, J.E. and Plosker, G.L., *Drugs* 63 (2003) 2079-2105).

There are few reports in the literature on attempts to produce modified PQQ-dependent s-GDHs with altered substrate specificity. Igarashi, S., et al., *Biochem. Biophys. Res. Commun.* 264 (1999) 820-824 report that introducing a point mutation at position Glu277 leads to mutants with altered substrate specificity profile.

Sode, EP 1 176 202, reports that certain amino acid substitutions within s-GDH lead to mutant s-GDH with an improved affinity for glucose. In EP 1 167 519 the same author reports on mutant s-GDH with improved stability. Furthermore the same author reports in JP2004173538 on other s-GDH mutants with improved affinity for glucose.

Kratzsch, P. et al., WO 02/34919 report that the specificity of s-GDH for glucose as compared to other sugar substrates, especially as compared to maltose, can be improved by amino acid substitutions in certain positions of s-GDH. Central and crucial is a substitution at amino acid position 348. A mutant s-GDH comprising for example a glycine in position 348 instead of a threonine as present in the wild-type s-GDH has a tremendously improved selectivity for the substrate glucose as, e.g. as compared to the substrate maltose. They also disclose that a double mutant having substitutions at positions 348 and 428 have an even more improved specificity for glucose.

5 In WO 2006/008132 it is shown that an amino acid insertion between amino acids 428 and 429 of s-GDH, especially in combination with an appropriate amino acid substitution at position 348 has quite favorable effects on substrate specificity. Mutants comprising this insertion are for example more specific for the substrate glucose as compared to the substrate maltose.

10 However, whereas quite some improvements on glucose specificity have been reported, it appears that such improvements frequently and unfortunately go hand in hand with disadvantages like e.g. a reduced stability, a reduced activity and/or a reduced affinity for glucose of such mutated s-GDH. For example, it has become evident that the improved specificity of an s-GDH mutant comprising an amino acid substitution in position 348 goes to the expense of stability, affinity and activity of said mutant as compared to the wild-type enzyme.

15 A great demand and clinical need therefore exists for further improved mutant forms of s-GDH having a high specificity for glucose and which feature at the same time a reasonable thermo stability, as well as improvements in specific activity or affinity for glucose, or that feature improvements in both specific activity and affinity for glucose.

20 It was the task of the present invention to provide new mutants or variants of s-GDH with significantly improve thermo stability, specific activity and affinity for glucose as compared to a mutant with improved specificity comprising a substitution at position 348.

25 It has been found that it is possible to significantly improve the thermo stability, the specific activity and the affinity for glucose of an s-GDH mutant having a substitution at position 348 by selecting mutations from the positions as given in the appending claims.

30 Due to the improved properties of the new forms of s-GDH, significant technical progress for glucose determinations in various fields of applications is possible. The improved s-GDH mutants according to this invention can for example be used with great advantage for the specific detection or measurement of glucose in biological samples.

Summary of the Invention

The present invention relates to mutants of s-GDH. A mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) is disclosed with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine and wherein said mutant additionally comprises at least one mutation for improving the stability of the mutant, at least one mutation for improving the affinity of the mutant to glucose, and optionally one or more mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose, and wherein the positions given correspond to the amino acid positions known from the *A. calcoaceticus* s-GDH wild-type sequence (SEQ ID NO: 2)

Also disclosed are an isolated polynucleotide encoding an s-GDH mutant protein, an expression vector comprising said isolated polynucleotide operably linked to a promoter sequence capable of promoting the expression of said polynucleotide in a host cell and a host cell comprising said expression vector.

Further a process for producing s-GDH mutants comprising culturing the host cell transfected with an appropriate expression vector under conditions suitable for production of an s-GDH mutant is described.

Further disclosed is a method of detecting, determining or measuring glucose in a sample using an improved s-GDH mutant according to the present invention, said improvement comprising contacting the sample with said mutant.

Also described is a device for the detection or measurement of glucose in a sample comprising an improved s-GDH mutant according to the present invention and other reagents required for said measurement.

Detailed Description of the Invention

In a first embodiment the invention relates to a mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine and wherein said mutant comprises at least one mutation for improving the stability of the mutant and additionally comprises at least one mutation for improving the affinity of the mutant to glucose, and optionally one or more mutation(s) for further improving the specificity of the mutant for glucose as

compared to maltose, and wherein the positions given correspond to the amino acid positions known from the *A. calcoaceticus* s-GDH wild-type sequence (SEQ ID NO: 2)

5 As described in WO 02/34919, a substitution of the amino acid in position 348 of the s-GDH sequence corresponding to the wild-type sequence isolated from *A. calcoaceticus*, can be used to significantly improve the glucose specificity of s-GDH. This is why the improvements described in the framework of the present invention are all described and based on an s-GDH mutant comprising an amino acid substitution at position 348. Preferably the residue threonine at position 348 is substituted with an amino acid residue selected from the group consisting of
10 alanine, glycine, and serine. In a further preferred embodiment glycine or serine is used to substitute for threonine at position 348. The terminology T348G is known to the skilled artisan and indicates that threonine at position 348 is replaced by glycine.

15 As discussed herein above, two completely different quinoprotein enzyme types with glucose dehydrogenase activity (membrane bound and soluble) are grouped together under EC 1.1.5.2. These two types appear not be related to each other.

For the purpose of this invention only the soluble form of GDH (s-GDH) is relevant and improved mutants thereof are discussed herein below.

20 It is known in the art that the wild-type DNA-sequence of a soluble PQQ-dependent glucose dehydrogenase can be isolated from strains of *Acinetobacter*. Most preferred is the isolation of s-GDH from the *Acinetobacter calcoaceticus*-type strain LMD 79.41. The polypeptide sequence of this wild-type s-GDH (the mature protein) is given in SEQ ID NO: 2 and the DNA sequence is given in SEQ ID NO: 1,
25 respectively. Other LMD strains of *Acinetobacter* may also be used as source of wild-type s-GDH. Such sequences can be aligned to the sequence obtained from *A. calcoaceticus* and sequence comparisons be made. It also appears feasible to screen DNA-libraries of other bacterial strains, as for example described for *E.coli* K-12 (Oubrie, A., et al., J. Mol. Biol. 289 (1999) 319-333) and to identify sequences
30 related to s-GDH in such genomes. Such sequences and yet unidentified homologous sequences may be used to generate s-GDH mutants with improved thermo stability.

The achievements of the present invention are described in great detail by making reference to amino acid positions known from SEQ ID NO: 2, the wild-type sequence of s-GDH as isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41. Amino acid positions in different s-GDH isolates corresponding to positions of SEQ ID NO: 2 are easily identified by appropriate sequence comparison.

The multiple alignment and comparison of an s-GDH sequence with the wild-type sequence of SEQ ID NO: 2 preferably is performed with the PileUp program of GCG Package Version 10.2 (Genetics Computer Group, Inc.). PileUp creates a multiple sequence alignment using a simplification of the progressive alignment method of Feng, D. F. and Doolittle, R. F., J. Mol. Evol. 25 (1987) 351-360, and the scoring matrixes for identical, similar, or different amino acid residues are defined accordingly. This process begins with the pair wise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster can then be aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences can be aligned by a simple extension of the pair wise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pair wise alignments that include increasingly dissimilar sequences and clusters, until all sequences have been included in the final pair wise alignment. This way amino acid positions in other, homologous s-GDH molecules can be easily identified as corresponding to the positions given for *A. calcoaceticus* s-GDH in SEQ ID NO: 2. This is why the amino acid positions given herein shall be understood as amino acid positions of SEQ ID NO: 2 or as the positions corresponding thereto in another, homologous s-GDH molecule.

The term "mutant" or "variant" in the sense of the present invention relates to an s-GDH protein which compared to the wild-type amino acid sequence given in SEQ ID NO: 2 exhibits at least one amino acid substitution, deletion or insertion.

The s-GDH mutant may comprise other substitutions and/or deletions and/or insertions provided that an s-GDH mutant of the invention does not differ by more than 45 amino acids from the s-GDH of SEQ ID NO: 2, e.g. that it exhibits at most 45 amino acid substitutions, insertions or deletions in total.

The term "a mutation for improving the stability" refers to any amino substitutions and/or deletions and/or insertions improving the thermo stability of an s-GDH mutant in a short term temperature stress model.

As mentioned above, improvements in glucose specificity appear to be possible only and largely at the expense of a reduced stability, a reduced affinity to glucose or a reduced specific activity or to any combinations of these disadvantageous properties.

5 Stability according to the present invention is assessed in such a short term stress model and the s-GDH stability as determined in this model is referred to as thermo stability. Thermo stability is determined by measuring the unstressed and stressed s-GDH enzyme activity of a sample. By setting the unstressed sample activity to 100% the remaining activity after stress treatment can be calculated in percent. For
10 mutants of s-GDH with improved substrate specificity, stressing conditions of 64°C for 30 minutes were chosen. Using these conditions the wild-type enzyme has about 80 % of its original activity left, whereas most of the mutants with improved specificity for glucose have only 10 % or less of their initial enzymatic activity left after subjecting them to this short-term stress model.

15 Preferably the mutation for improving the stability of an s-GDH variant having a substitution of threonine at position 348 by either glycine, alanine or serine is a substitution. Preferably said substitution is selected from the group consisting of D87R; N122K; S124K; S146A or G; L187F or M; N267Y; V298L; T313D and L386F.

Also preferred said substitution for improving the stability of an s-GDH variant is
20 selected from the group consisting of D87R; N122K; S124K; S146G; V298L and L386F. In further preferred embodiments combinations of two, three or of four these substitutions or also preferred of all these five substitutions are used in a mutated s-GDH to improve the stability of such mutant.

In a preferred embodiment the s-GDH mutant according to the present invention
25 comprises an arginine in position 87 as known from *A. calcoaceticus* wild-type s-GDH (SEQ ID NO: 2) or in a position corresponding to said position 87 in a homologous enzyme.

In a further preferred embodiment the s-GDH mutant according to the present invention comprises a lysine in position 122 as known from *A. calcoaceticus* wild-type s-GDH (SEQ ID NO: 2) or in a position corresponding to said position 122 in
30 a homologous enzyme.

In a further preferred embodiment the s-GDH mutant according to the present invention comprises a lysine in position 124 as known from *A. calcoaceticus* wild-

type s-GDH (SEQ ID NO: 2) or in a position corresponding to said position 124 in a homologous enzyme.

5 In a further preferred embodiment the s-GDH mutant according to the present invention comprises glycine in position 146 as known from *A. calcoaceticus* wild-type s-GDH (SEQ ID NO: 2) or in a position corresponding to said position 146 in a homologous enzyme.

10 In a further preferred embodiment the s-GDH mutant according to the present invention comprises leucine in position 298 as known from *A. calcoaceticus* wild-type s-GDH (SEQ ID NO: 2) or in a position corresponding to said position 298 in a homologous enzyme.

In a further preferred embodiment the s-GDH mutant according to the present invention comprises phenylalanine in position 386 as known from *A. calcoaceticus* wild-type s-GDH (SEQ ID NO: 2) or in a position corresponding to said position 386 in a homologous enzyme.

15 It has been found that six positions of s-GDH appear to be rather important for achieving significant improvements in terms of thermo stability, i.e., positions 87, 122, 124, 146, 298 and 386. What is of significant relevance here is the fact that it has been found that these substitutions have a pronounced effect on the thermo stability of mutants which previously had been generated in order to improve
20 glucose specificity, but at the expense of a reduced thermo stability. In a preferred embodiment the s-GDH mutant according to the present invention comprises a an arginine in position 87, a lysine in position 122 and 124, a glycine in position 146, a leucine in position 298 and a phenylalanine in position 386 of SEQ ID NO:2, or in a position corresponding to said positions if a homologous s-GDH is used.

25 In a further preferred embodiment the present invention relates to a mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 either by glycine, or by alanine or by serine, wherein said mutant additionally comprises at least one mutation for improving the stability of
30 the mutant and at least one mutation for improving the affinity for glucose of the mutant.

The term "affinity" for a substrate is well known in the art. It is given in mM as the so-called Km-value. Various methods are known to the art to determine the affinity

of s-GDH, using glucose or other sugars as substrates, cf., Igarashi, S., et al., Biochem Biophys Res Commun 264 (1999) 820.

In the screening of new variants with crude *E. coli* extract a percentage calculation of the Km-value was performed for faster evaluation of clones generated. The
5 affinity towards glucose for candidate s-GDH mutants was calculated according to the well-known Michaelis-Menten-kinetics.

The s-GDH mutant according to the present invention has an improved affinity for glucose as compared to a mutant comprising a substitution of threonine at position 348 by either glycine, alanine or serine. Preferably the affinity for the substrate
10 glucose is determined as described in detail in the examples section.

Preferably the one or more mutation for improving the affinity for glucose of an s-GDH mutant already comprising a substitution of threonine at position 348 by either glycine, alanine or serine is an amino acid substitution selected from the group consisting of L110H or Y; N229A, G or S; Q246H, M or N; Y333A; G339T;
15 M341V; V349A or G and V436P.

In case the amino acid corresponding to position 110 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 2) is substituted in a variant of the present invention, it is preferred that the naturally occurring amino acid leucine is substituted by an amino acid selected from the group consisting of histidine and
20 tyrosine. More preferred the substitution in position 110 is by histidine.

In case the amino acid corresponding to position 229 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 2) is substituted in a variant of the present invention, it is preferred that the naturally occurring amino acid asparagine is substituted by an amino acid selected from the group consisting of
25 alanine, glycine and serine. More preferred the substitution in position 229 is by alanine.

In case the amino acid corresponding to position 349 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 2) is substituted in a variant of the present invention, it is preferred that the naturally occurring amino acid valine is substituted by an amino acid selected from the group consisting of alanine and
30 glycine. More preferred the substitution in position 349 is by glycine.

Also preferred, the mutation for improving the affinity for glucose is selected from the group consisting of L110H, Q246H; G339T; M341V, V349G and V436P.

Also preferred said substitution for improving the affinity for glucose is selected from Q246H; G339T; M341V and V349G. A preferred s-GDH according to the present invention comprises two or three of these substitutions or all these four substitutions.

In a further preferred embodiment the above described s-GDH mutant with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine and comprising at least one mutation for improving the stability additionally comprises one or more mutation(s) for improving the substrate specificity of the mutant to glucose as compared to maltose.

For certain applications the substrate specificity of an s-GDH mutant with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine may not yet be sufficient for certain routine applications.

In certain embodiments it may be required to generate an s-GDH mutant that in addition to the above discussed mutation at position 348 comprises one or more additional mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose.

The term "substrate specificity" or "specificity" is well-known to the skilled artisan.

In order to calculate the substrate specificity or cross-reactivity one easy way is to set the activity measured with glucose as substrate to 100 % and to compare the activity measured with the other selected sugar to the glucose value. Sometimes, in order not to be redundant, simply the term specificity is used without making special reference to glucose on the one hand and a selected other sugar substrate on the other hand.

The expert in the field will appreciate that comparison of enzymatic activities is best made at equimolar concentrations of the substrate molecules investigated using well-defined assay conditions. Otherwise corrections for differences in concentrations have to be made.

Standardized and well-defined assay conditions have to be chosen in order to assess (improvements in) substrate specificity. The enzymatic activity of s-GDH for glucose as a substrate as well as for other selected sugar substrates is measured as described in the Examples section.

- 5 Based on the measurements of enzymatic activity for glucose or for maltose, respectively, cross-reactivity (and improvement thereof) is assessed.

The s-GDH (cross-) reactivity for maltose in percent is calculated as

Cross-reactivity [%] = (activity maltose/activity glucose) x 100%.

- 10 (Cross-) reactivity for maltose of wild-type s-GDH according to the above formula has been determined as about 105% (see WO 02/34919).

Specificity is calculated according to the following formula:

$$\text{specificity} = \frac{\text{activity glucose mutant}}{\text{activity maltose mutant}} \times \frac{\text{activity maltose wild-type}}{\text{activity glucose wild-type}}$$

15

Improvements in specificity of a novel s-GDH mutant are recognized as smaller values in the above calculation, as compared to an s-GDH mutant with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine.

- 20 As the skilled artisan will appreciate the absolute numbers will depend on the number and kind of mutations already present in a mutant. The number and kind of mutations already present in a mutant may be termed the mutant back-ground. Any novel mutation is best compared directly to the mutant back-ground.

- 25 Preferably the mutation for further improving the substrate specificity for glucose as compared to maltose is an amino acid substitution selected from the group consisting of Q145P; D163G or N; Q164F; L169F; Y171G; I208L or V; T224I; E245D; G276S; A294D or E; V300A, S, N, Y or I; T307G; T323V; A354Y, E or L; R378I, M, A or D; N428P and insertion 429 P. The term "insertion 429" is used to indicate that between position 428 and position 429 of SEQ ID NO:2 a proline is inserted.
- 30

In case the amino acid corresponding to position 169 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 2) is substituted in a variant of

the present invention, it is preferred that the naturally occurring amino acid leucine is substituted by phenylalanine, tyrosine or tryptophane. More preferred the substitution in position 169 is by phenylalanine.

5 In case the amino acid corresponding to position 171 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 2) is substituted in a variant of the present invention, it is preferred that the naturally occurring amino acid tyrosine is substituted by an amino acid selected from the group consisting of from the group consisting of alanine, methionine, glycine. More preferred the substitution in position 171 is by glycine.

10 In case the amino acid corresponding to position 245 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 2) is substituted in a variant of the present invention, it is preferred that the naturally occurring amino acid glutamic acid is substituted by aspartic acid, asparagine or glutamine. More preferred the substitution in position 245 is by aspartic acid.

15 In case the amino acid corresponding to position 341 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 2) is substituted in a variant of the present invention, it is preferred that the naturally occurring amino acid methionine is substituted by valine, alanine, leucine or isoleucine. More preferred the substitution in position 341 is by valine.

20 It has been also found that it is possible to further improve substrate specificity of an s-GDH variant already comprising a substitution at position 348 by insertion of an amino acid, preferably a proline, between position 428 and 429.

Also preferred, the additional mutation for improving the substrate specificity for glucose as compared to maltose is selected from the group consisting of L169F; 25 Y171G; E245D; N428P and insertion 429P.

Preferably, the additional mutation for improving the substrate specificity for glucose as compared to maltose is selected from the group consisting of L169F; Y171G; E245D; and N428P. In further preferred embodiments combinations of two, three or all these four substitutions are used to improve the substrate 30 specificity for glucose as compared to maltose of such mutant. Also preferred, the additional mutation for improving the substrate specificity for glucose as compared to maltose is selected from the group consisting of L169F; Y171G; E245D; and insertion 429P. In further preferred embodiments combinations of two or of all

- 16 -

three substitutions are used together with the insertion 429 P in a mutated s-GDH to improve the substrate specificity for glucose as compared to maltose of such mutant.

5 As described in WO 02/34919 and WO 2006/008132, respectively, a substitution at position 428 whereby asparagine is replaced by proline or an insertion of the amino acid proline between position 428 and 429, respectively, further improve the specificity of an s-GDH mutant already comprising a substitution at position 348. In a further preferred embodiment the present invention therefore relates to a mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2)
10 with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either by glycine, by alanine or by serine and either a substitution at position 428 whereby asparagine is replaced by proline or an insertion of the amino acid proline between position 428 and 429, wherein said mutant additionally comprises at least one mutation for improving the stability of
15 the mutant, at least one mutation for improving the specific activity of the mutant, and optionally one or more mutation(s) for improving the affinity of the mutant to glucose, and/or one or more mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose, and wherein the positions given correspond to the amino acid positions known from the *A. calcoaceticus* s-GDH wild-type sequence (SEQ ID NO: 2)
20

In another embodiment the present invention relates to a mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine, wherein said mutant additionally
25 comprises at least one mutation for improving the stability of the mutant and at least one mutation for improving the specific activity of the mutant.

The term "specific activity" is well-known from the art. It is used to describe the enzymatic activity per amount of protein. Various methods are known to the art to determine specific activity of an s-GDH, using glucose or other sugars as substrates,
30 see for example Igarashi, S., et al., Biochem Biophys Res Commun 264 (1999) 820. The s-GDH mutant according to the present invention has an improved specific activity for the substrate glucose as compared to a mutant comprising a substitution of threonine at position 348 by either glycine, alanine or serine.

Preferably the mutation for improving the specific activity for glucose is an amino acid substitution selected from the group consisting of H30F or R; A301G or S and A302S or T.

5 As the skilled artisan will appreciate, it is possible to undertake amino acid substitutions, e.g. silent mutations, which do not influence the properties of s-GDH to a significant extend. The variant according to the present invention will, however, have no more than 45 amino acid exchanges as compared to SEQ ID NO:2. Preferably, the variant will comprise 20 or less amino acid substitutions, more preferred, only 15 amino acid substitutions or fewer substitutions will be
10 present.

Some specific s-GDH variants according to the present invention are given in the Examples section. Preferred s-GDH variants with low glucose interference and improved characteristics regarding thermo stability and substrate affinity for glucose comprise the mutants with the following substitutions:

15 N122K+L169F+Y171G+E245D+M341V+T348G+ins429P;
N122K+S124K+L169F+Y171G+E245D+M341V+T348G+ins429P;
N122K+S124K+L169F+Y171G+E245D+M341V+T348G+L386F+ins429P;
N122K+S124K+L169F+Y171G+E245D+Q246H+M341V+T348G+L386F
+ins429P;
20 D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+
M341V+T348S+L386F+ins429P;
D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+
+G339T+M341V+T348G+L386F+ins429P;
D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+
25 M341V+T348S+L386F+ins429P+V436P;
D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+
M341V+T348S+V349G+A354T+L386F+ins429P;
D87R+L110H+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+
M341V+T348S+L386F+ins429P.

30 Numerous possibilities are known in the art to produce mutant proteins. Based on the important findings of the present invention disclosing the critical importance of certain residues to improve the thermo stability, the affinity for glucose and the substrate specificity of a mutant s-GDH the skilled artisan now can easily produce

further appropriate variants of s-GDH harboring these and other favorable modifications. Such variants for example can be obtained by the methods known as random mutagenesis (Leung, D. W., et al., Technique 1 (1989) 11-15) and/or site directed mutagenesis (Hill, D. E., et al., Methods Enzymol. 155 (1987) 558-568). An alternative method to produce a protein with the desired properties is to provide chimaeric constructs, which contain sequence elements from at least two different sources or to completely synthesize an appropriate s-GDH gene. Such procedures known in the art may be used in combination with the information disclosed in the present invention to provide mutants or variants of s-GDH comprising e.g. additional amino acid substitutions in combination with the known critical importance of a substitution in position 348 of SEQ ID NO: 2.

An s-GDH variant according to the present invention can e.g., be produced by starting from an s-GDH gene as isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41 as well as by starting from a homologous sequence. In the context of this application the term "homologous" is meant to comprise an s-GDH amino acid sequence with at least 90 % identity as compared to SEQ ID NO: 2. With other words, after appropriate alignment using the PileUp program, at least 90 % of the amino acids of such homologous s-GDH are identical to the amino acids described in SEQ ID NO: 2.

It will be understood that variations of DNA and amino acid sequences naturally exist, or may be intentionally introduced using methods known in the art. These variations may result in up to 10 % amino acid differences in the overall sequence, due to deletions, substitutions, insertions, inversions or additions of one or more amino acid residues in said sequence as compared to SEQ ID NO: 2. Such amino acid substitutions may be made, for example, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with uncharged polar head groups or nonpolar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine. Other contemplated variations include salts and esters of the aforementioned polypeptides, as well as precursors of the aforementioned polypeptides, for example, precursors having an N-terminal substitution such as methionine,

N-formylmethionine used as leader sequences. Such variations may be made without necessarily departing from the scope and the spirit of the present invention.

According to procedures known in the state of the art or according to the procedures given in the examples section, it is possible to obtain polynucleotide sequences coding for any of the s-GDH mutants as discussed above. The invention therefore comprises also isolated polynucleotide sequences encoding s-GDH mutant proteins according to the present invention as described above.

The present invention further includes an expression vector comprising a nucleic acid sequence according to the present invention operably linked a promoter sequence capable of directing its expression in a host cell.

The present invention further includes an expression vector comprising a nucleic acid sequence according to the present invention operably linked to a promoter sequence capable of directing its expression in a host cell. Preferred vectors are plasmids such as pACSGDH shown in Figures 2 and 3.

Expression vectors useful in the present invention typically contain an origin of replication, an antibiotic resistance for selection, a promoter for expression and the whole or part of the s-GDH gene variant. The expression vectors may also include other DNA sequences known in the art, like signal sequences (for a better folding, transportation into the periplasma or secretion), inducers for a better modulation of the expression, or cleavage sites for cloning.

The characteristics of the selected expression vector must be compatible to the host cell, which is to be employed. For example, when cloning in an *E.coli* cell system, the expression vector should contain promoters isolated from the genome of *E.coli* cells (e.g., *lac*, or *trp*). Suitable origins of replication like the ColE1 plasmid replication origin can be used. Suitable promoters include, for example, *lac* and *trp*. It is also preferred that the expression vector includes a sequence coding for a selection marker like an antibiotic resistance gene. As selectable markers, ampicillin resistance, or canamycin resistance may be conveniently employed. All of these materials are known in the art and are commercially available.

Suitable expression vectors containing the desired coding and control sequences may be constructed using standard recombinant DNA techniques known in the art, many of which are described in Sambrook et al., in "Molecular Cloning:

A Laboratory Manual" (1989) Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press.

5 The present invention additionally relates to host cells containing an expression vector which comprises a DNA sequence coding for all or part of the mutant s-GDH. The host cells preferably contain an expression vector that comprises all or part of one of the DNA sequences coding for a mutant s-GDH having one or more mutations shown in the Examples 2-8. Suitable host cells include, for example, *E.coli* HB101 (ATCC 33694) available from Promega (2800 Woods Hollow Road, Madison, WI, USA), XL1-Blue MRF' available from Stratagene (11011 North
10 Torrey Pine Road, La Jolla, CA, USA) and the like.

Expression vectors may be introduced into host cells by various methods known in the art. For example, transformation of host cells with expression vectors can be carried out by polyethylene glycol mediated protoplast transformation method (Sambrook et al. 1989, supra). However, other methods for introducing expression
15 vectors into host cells, for example, electroporation, bolistic injection, or protoplast fusion, can also be employed.

Once an expression vector containing an s-GDH variant has been introduced into an appropriate host cell, the host cell may be cultured under conditions permitting expression of the desired s-GDH variants. Host cells containing the desired
20 expression vector with the DNA sequence coding for all or part of the mutant s-GDH can be easily identified by i.e. antibiotics selection. The expression of the s-GDH variants can be identified by different methods like measuring production of s-GDH mRNA transcripts, detection of the gene product immunologically or detection of the enzymatic activity of the gene product. Preferably an enzymatic
25 assay is applied.

The present invention also teaches the generation and screening of s-GDH mutants. Random mutagenesis and saturation mutagenesis is performed as known in the art. Variants are screened for thermo stability (activity without heat stress treatment compared to remaining activity after heat stress treatment). The assay conditions
30 chosen are adapted to ensure that the expected small enhancements brought about e.g., by a single amino acid substitution, can be measured. One preferred mode of selection or screening of appropriate mutants is given in Example 3. Any change or improvement as compared to the starting enzyme (mutant or wild-type) can be clearly detected.

It should, of course, be understood that not all expression vectors and DNA regulatory sequences would function equally well to express the DNA sequences of the present invention. Neither will all host cells function equally well with the same expression system. However, one of ordinary skill in the art will make an appropriate selection among the expression vectors, DNA regulatory sequences, and host cells using the guidance provided herein without undue experimentation.

The invention also relates to a process for producing s-GDH variants of the current invention comprising culturing a host cell of the invention under conditions suitable for production of the mutant s-GDH of the invention. For bacterial host cells, typical culture conditions are liquid medium containing carbon and nitrogen sources, the appropriate antibiotic and induction agent (depending on the used expression vector). Typical appropriate antibiotics include ampicillin, canamycin, chloroamphenicol, tetracycline and the like. Typical induction agents include IPTG, glucose, lactose and the like.

It is preferred that the polypeptides of the present invention are obtained by production in host cells expressing a DNA sequence coding the mutant s-GDH. The polypeptides of the present invention may also be obtained by *in vitro* translation of the mRNA encoded by a DNA sequence coding for the mutant s-GDH. For example, the DNA sequences may be synthesized as described above and inserted into a suitable expression vector, which in turn may be used in an *in vitro* transcription/translation system.

An expression vector comprising an isolated polynucleotide as defined and described above operably linked to a promoter sequence capable of promoting its expression in a cell-free peptide synthesis system represents another preferred embodiment of the present invention.

The polypeptides produced e.g. by procedures as describe above, may then be isolated and purified using various routine protein purification techniques. For example, chromatographic procedures such as ion exchange chromatography, gel filtration chromatography and affinity chromatography may be employed.

One of the major applications of the improved s-GDH variants of this invention is for the use in test strips to monitor the blood-glucose level in diabetic patients. The insensitivity of PQQ-dependent glucose dehydrogenase towards oxygen is, as discussed above, a big advantage over glucose oxidase. The interference due to e.g.,

5 maltose, galactose, and/or other related sugars which may be present in a sample to be analyzed, can now be significantly reduced using the novel s-GDH variants having both improved thermo stability as well as improved specificity towards glucose. Of course many kinds of samples may be investigated. Bodily fluids like serum, plasma, intestinal fluid or urine are preferred sources for such samples.

10 The invention also comprises a method of detecting, determining or measuring glucose in a sample using an s-GDH mutant according to the present invention. It is especially preferred that the improved method for detection of glucose in a sample is characterized in that said detection, determination or measurement of glucose is performed using a sensor or test strip device.

Also within the scope of the present invention is a device for the detection or measurement of glucose in a sample comprising an s-GDH mutant according to this invention as well as other reagents required for said measurement.

15 The s-GDH variants with improved thermo stability of this invention can also be used to great advantage in biosensors (D'Costa, E.J., et al., Biosensors 2 (1986) 71-87; Laurinavicius, V., et al., Analytical Letters 32 (1999) 299-316; Laurinavicius, V., et al., Monatshefte fuer Chemie 130 (1999) 1269-1281; Woosuck, S. et al., Sensors and Actuators B 100 (2004) 395-402) for online monitoring of glucose in a sample or a reactor. For this purpose, the s-GDH variants can, for example, be used to coat
20 an oxygen-insensitive glassy electrode with an osmium complex containing a redox conductive epoxy network (Ye et al., 1993 supra) for more accurate determination of the glucose concentration.

25 In the following examples, all reagents, restriction enzymes, and other materials were obtained from Roche Diagnostics Germany, unless other commercial sources are specified, and used according to the instructions given by the suppliers. Operations and methods employed for the purification, characterization and cloning of DNA are well known in the art (Ausubel, F., et al., in "Current protocols in molecular biology" (1994) Wiley Verlag) and can be adapted as required by the skilled artisan.

30 The following examples further illustrate the present invention. These examples are not intended to limit the scope of the present invention, but provide further understanding of the invention.

The following examples, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

5 **Description of the Figures**

Figure 1: Protein sequences of *A. calcoaceticus* PQQ-dependent s-GDH (top) and *A. baumannii* s-GDH (bottom) aligned according to sequence homology.

10 Figure 2: Illustration of pACSGDH vector referred to in Example 1 containing the wild-type or mutated DNA sequences, respectively, of soluble PQQ-dependent glucose dehydrogenase.

Figure 3: Nucleotide (DNA) sequence of the pACSGDH vector referred to in Example 1 containing the wild-type DNA sequence of soluble PQQ-dependent glucose dehydrogenase.

15 **Example 1**

Cloning and expression of the wild-type *A. calcoaceticus* soluble PQQ-dependent glucose dehydrogenase in *E. coli*

20 The s-GDH gene was isolated from *Acinetobacter calcoaceticus* strain LMD 79.41 according to standard procedures. The wild-type s-GDH gene was subcloned into a plasmid containing the *mgl* promoter for adjustable expression (cf. Patent application WO 88/09373). The new construct was called pACSGDH (see Figures 2 and 3 as well as SEQ ID NO: 3). The recombinant plasmids were introduced into a host organism selected from the *E.coli* group. These organisms were then cultivated under appropriate conditions and colonies showing s-GDH activity selected.

25 The plasmid pACSGDH was isolated from a 200 ml over-night culture of the clone mentioned above using the QIAGEN Plasmid Maxi Kit (Qiagen) according to the manufacturers' protocol. The plasmid was resuspended in 1 ml bi-distilled water. The concentration of the plasmid was determined using a Beckman DU 7400 Photometer.

30 The yield was 600 µg. Then the quality of the plasmid was determined by agarose gel electrophoresis.

Example 2**Generating mutant T348G and mutant T348S**

As starting templates for the generation of further improved variants mutated s-GDH with the mutations T348G or T348S, respectively, was manufactured. These mutants of s-GDH were chosen because they are known to have improved substrate specificity for glucose as compared to the substrate maltose (see WO 02/34919).

The QuickChange Site-Directed Mutagenesis Kit (Stratagene, Cat. 200518) was used to substitute the threonine at position 348 by a glycine or a serine. The appropriate primers were designed.

The 5'- and the 3'-primer used for mutagenesis were complementary to each other and contained the modified codon for the exchange from threonine to glycine (ACA to GGG) or from threonine to serine (ACA to TCA) in a central position. These nucleotides were flanked by 12 to 16 nucleotides at each end. The sequences of the nucleotides were identical to the sense and anti-sense DNA-strand flanking the codon for the amino acid exchange. Instead of the codons ACA = threonine for the sense and TGT for the anti-sense strand, respectively, the primers contained GGG = glycine or TCA = serine, respectively, for the sense and CCC = glycine or AGT = serine, respectively, for the anti-sense strand. The sense and the antisense strand for the exchange T348G are given as SEQ ID NOs: 3 and 4, respectively.

CATTTGCTGG CCAGGGGTTG CACCGTCAT (=SEQ ID NO: 4)
ATGACGGTGC AACCCCTGGC CAGCAAATG (=SEQ ID NO: 5)

The PCR-reaction and the *DpnI* digestion were performed according to the manual. After that, 1 µl of sample was used for the electroporation of XL-MRF'- cells. Electroporation was achieved with 2.5 KV in 0.2 cm cuvettes using a BioRad *E. coli* Pulser (BioRad). After growth in 1 ml LB at 37 °C for one hour, bacteria were plated on "4 x yeast" medium (20 g yeast extract + 5 g NaCl, pH 7.0 to 1 l Aqua dest.)-Ampicillin agar plates (100 µg / ml Ampicillin) and grown over night at 37°C. The mutated s-GDH clones were examined using the following screening method.

Example 3

Screening

5 The mutant colonies on the agar plates described above were picked into microtiter plates (MTPs) containing 200 μ l "4 x yeast"-Ampicillin-medium per well and incubated over night at 37 °C. These plates are called master plates.

10 From each master plate, 5 μ l sample/well was transferred to an MTP containing 5 μ l per well of B (B = Bacterial Protein Extraction Reagent; Pierce No. 78248) for cell disruption and 240 μ l of 0.0556 mM pyrroloquinoline quinone (PQQ); 50 mM Hepes; 15 mM CaCl_2 pH 7.0/well for activation of s-GDH were added. To complete the formation of the holoenzyme, the MTP was incubated at 25°C for 2 hours and at 10 °C over night. This plate is called working plate.

15 From the working plate 4 x 10 μ l sample per well were transferred to four empty MTPs. Thereafter, the first aliquot was tested with glucose at standard concentration (i.e. 30 mM), the second one with a reduced glucose concentration (1.9 mM instead of 30 mM), the third one with maltose as a substrate and the fourth stressed 30 min at 64 °C before testing that aliquot alike the first aliquot. All selected other sugar molecules were used in equimolar standard concentration, i.e. at 30 mM. For all assays 90 μ l of mediator solution (see Example 8) already containing the sugar to be analyzed was applied.

20 The dE/min was calculated and the value using 30 mM glucose as substrate was set to 100% activity. The value obtained with the other sugar was compared to the glucose value and calculated in percent activity ((e.g. for maltose as: dE/min maltose/dE glucose)*100). This is equivalent to the cross-reactivity of the (variant) enzyme. In the following Tables "M/G", i.e. the cross-reactivity of s-GDH with maltose (M) as substrate as compared to glucose (G) as substrate is given.

25 The value obtained with the 1.9 mM glucose was compared to the 30 mM glucose value and calculated in percent relative activity ((dE/min 1.9 mM glucose/30 mM glucose)*100). This gives a %-value which is an indirect indicator of the Km-value for the variant analyzed. According to this calculation a higher %-value indicates a lower (= better) Km-value.

30

Table 1: Basic characteristics of the mutants T348G and T348S as compared to wild-type (WT) s-GDH

Enzyme	M/G at 30 mM sugar in %	% relative activity 1,9 mM / 30 mM glucose	Stability, 30 min, 64 °C	Amino acid (AA) exchange
WT	105 %	70%	80 %	-
Mutant A	22 %	25 %	40 %	T348G
Mutant A'	50 %	35 %	50 %	T348S

Example 4

5 Sequencing of a mutant s-GDH

The method is exemplified for s-GDH T348G. The sequencing detailed below can also be used for sequencing of other s-GDH mutants.

The following primers were used for sequencing of an s-GDH mutant:

Sense strand: 5'-TTA ACG TGC TGA ACA GCC GG-3' (= SEQ ID NO:6)

10 Anti-sense strand: 5'-ATA TGG GTA AAG TAC TAC GC -3' (= SEQ ID NO: 7)

The plasmids containing the gene for mutant s-GDH T348G, which mutant has about 22 % maltose/glucose cross-reactivity and s-GDH T348S, which mutant has 50 % maltose/glucose cross-reactivity, respectively, were isolated (High Pure Plasmid Isolation Kit, Roche Diagnostics GmbH, No.1754785) and sequenced using an ABI Prism Dye Terminator Sequencing Kit and ABI 3/73 and 3/77 sequencer (Amersham Pharmacia Biotech).

15

Sequencing confirmed that the desired mutations on DNA and on amino acid level have been achieved for both mutants. This did result in an exchange from T to G or to S, respectively, at position 348. No additional mutation on the two genes has been found.

20

Example 5

Further s-GDH mutants obtained by saturation mutagenesis on the basis of T348G (mutant A) and T348S (mutant A')

Candidate amino acid positions were known to the inventors from previous studies conducted by them. These candidate amino acid positions were suspected or

25

known to influence relevant characteristics of s-GDH like thermo stability, substrate specificity or affinity to glucose were analyzed individually on basis of either T348G (mutant A) or on basis of T348S (mutant A').

5 Saturation mutagenesis was performed for single amino acid positions in order to evaluate which effect such single amino acid substitution might have on the mutant T348G or T348S, respectively.

The QuickChange Site-Directed Mutagenesis Kit (Stratagene, Cat. 200518) was used to substitute successively wild type amino acids at positions 87, 110, 122, 124, 145, 146, 169, 171, 187, 246, 294, 298, 300, 313, 323, 333, 339, 341, 349, 378, 428, 10 and 436 of the wild-type s-GDH-protein, respectively.

The 5'- and the 3'-primer used for mutagenesis were chosen to be complementary to each other and contained NNN (N = A, C, G or T) in a central position. The three randomly incorporated nucleotides N, which are at the desired position and coding for the amino acid position under investigation were flanked by 12 to 16 15 nucleotides at each end which were identical to the sense and antisense DNA-strand of the template. Instead of the wild-type codon, the primers contained NNN therefore the oligonucleotides coded for every possible codon.

For each of the positions under investigation, one PCR reaction was performed.

20 The PCR-reactions and the DpnI-restriction endonuclease digestions were performed according to the manual provided with the QuickChange Site-Directed Mutagenesis Kit (Stratagene, Cat. 200518) .

From each PCR reaction 1 µl was used for the electroporation of XL1F-cells. Cells were grown and the s-GDH-activities of the clones were determined as described above.

25 To increase the statistical likelihood that all 20 possible amino acids substitutions are covered in this evaluation, 200 clones for each position were screened as described in Example 3. Interesting clones were sequenced according to the method given in Example 4.

Table 2: Effect of additional amino acid substitutions on basic characteristics of mutant A (=T348G)

Enzyme	M/G at 30 mM sugar in %	% relative activity 1.9 mM / 30 mM glucose	Stability, 30 min, 64 °C	Amino acid (AA) exchange
Wt- GlucDOR	105 %	70 %	80 %	-
Mutant A	22 %	25 %	40 %	T348G
Mutant A/1	-	30 %	-	+ L 110 H
Mutant A/2	-	28 %	-	+ L110 Y
Mutant A/3	40 %	50 %	-	+ Q 246 H
Mutant A/4	33 %	30 %	-	+ Q 246 M
Mutant A/5	35 %	33 %	-	+ Q 246 N
Mutant A/6	-	30 %	-	+ Y 333 A
Mutant A/7	55 %	40 %	-	+ G 339 T
Mutant A/8	30 %	45 %	-	+ V 436 P
Mutant A/9	28 %	30 %	-	+ M 341 V
Mutant A/10	25 %	28 %	40 %	+ V 349 A
Mutant A/11	26 %	28 %	40 %	+ V 349 G
Mutant A/12	20 %	27 %	-	+ Q 145 P
Mutant A/13	17 %	30 %	-	+ A 294 D
Mutant A/14	15 %	30 %	-	+ A 294 E
Mutant A/15	20 %	28 %	-	+ V 300 A
Mutant A/16	20 %	28 %	-	+ V 300 S
Mutant A/17	20 %	28 %	-	+ V 300 N
Mutant A/18	20 %	28 %	-	+ V 300 Y
Mutant A/19	20 %	28 %	-	+ V 300 I
Mutant A/20	17 %	25 %	-	+ T 323 V
Mutant A/21	18 %	26 %	-	+ R 378 I
Mutant A/22	19 %	26 %	-	+ R 378 M
Mutant A/23	17 %	26 %	-	+ R 378 A
Mutant A/24	17 %	28 %	-	+ R 378 D
Mutant A/25	15 %	22 %	-	+ E 245 D
Mutant A/26	18 %	32 %	30 %	+ L 169 F
Mutant A/27	18 %	31 %	28 %	+ Y 171 G
Mutant A/28	12 %	20 %	20 %	+ Ins 429 P
Mutant A/29	-	-	50 %	+ D 87 R
Mutant A/30	-	-	70 %	+ S 146 A
Mutant A/31	-	-	75 %	+ S 146 G

- 29 -

Enzyme	M/G at 30 mM sugar in %	% relative activity 1.9 mM / 30 mM glucose	Stability, 30 min, 64 °C	Amino acid (AA) exchange
Mutant A/32	-	-	45 %	+ L 187 F
Mutant A/33	-	-	50%	+ N 122 K
Mutant A/34	-	-	45 %	+ S 124 K
Mutant B	10 %	35 %	50 %	T 348 G + N 428 P

Table 3: Effect of additional amino acid substitutions on basic characteristics of mutant A' (=T348S)

Enzyme	M/G at 30 mM sugar in %	% relative activity 1.9 mM / 30 mM glucose	Stability, 30 min, 64 °C	Amino acid (AA) exchange
Wt- GlucDOR	105 %	70 %	80 %	-
Mutant A'	50 %	35 %	50 %	T348S
Mutant A'/1	55 %	47 %	-	+ L 110 H
Mutant A'/2	65 %	70 %	-	+ Q 246 H
Mutant A'/3	58 %	50 %	-	+ Q 246 M
Mutant A'/4	60 %	55 %	-	+ Q246 N
Mutant A'/5	59 %	50 %	-	+ G 339 T
Mutant A'/6	60 %	60 %	-	+ V 436 P
Mutant A'/7	40 %	35 %	-	+ A 294 D
Mutant A'/8	38 %	32 %	-	+ A 294 E
Mutant A'/9	41 %	45 %	-	+ T 323 V
Mutant A'/10	43 %	47 %	-	+ R 378 I
Mutant A'/11	44 %	47 %	-	+ R 378 M
Mutant A'/12	40 %	50 %	-	+ R 378 A
Mutant A'/13	40 %	50 %	-	+ R 378 D
Mutant A'/14	-	-	60 %	+ D 87 R
Mutant A'/15	-	-	80 %	+ S 146 A
Mutant A'/16	-	-	85 %	+ S 146 G
Mutant A'/17	-	-	65 %	+ V 298 L
Mutant A'/18	-	-	60 %	+ T 313 D
Mutant A'/19	-	-	75 %	+L 386 F

- 5 Amino acid exchanges with a positive effect on substrate specificity, affinity for glucose and/or thermo stability of mutant A or mutant A', respectively can be derived from Tables 2 and 3.

Example 6**Identification of mutants with improved thermo stability**

Experiments have been expanded to mutants having rather good substrate specificity for glucose as compared to maltose, but at the cost of disadvantages like
5 too low thermo stability or a too low affinity for glucose.

So-called mutant 6 has a quite favorable low cross-reactivity to maltose that is only about 1.5% of the reactivity as measured for glucose. Mutant 6 is characterized by the amino acid substitutions Y171G, E245D, M341V and T348G and it has an insertion of a proline (ins429P) between positions 428 and 429.

10 The following primers were used to introduce these desired amino acid substitutions:

Sense strand 5'- CCTATAAGAAAAAGACAGATACGCTCG -3' (SEQ ID NO: 8)

Antisense strand 5'- CGAGCGTATCTGTCTTTTCTTATAGG-3' (SEQ ID: NO: 9)

15 D87R:

Sense strand 5'- TTCCATCCTCGAGAGATTGTCAAT-3' (SEQ ID NO: 10)

Antisense strand 5'-ATTGACAATCTCTCTGAGGATGGAA-3' (SEQ ID: NO: 11)

N122K and S124K:

20 Sense strand 5'-CGTTATACCTATAAGAAAAAGACAGATACGCTCG-3' (SEQ ID NO: 12)

Antisense strand 5'- CGAGCGTATCTGTCTTTTCTTATAGGTATAACG-3' (SEQ ID NO: 13)

S146G:

25 Sense strand 5'-AAAAGACCATCAGGGTGGTCTCGAGAAG -3' (SEQ ID NO: 14)

Antisense strand 5'-CTTCTCGAGACCACCCTGATGGTCTTTT -3' (SEQ ID: NO: 15)

V298L:

30 Sense strand 5'-GCTCAAAATGGATTAAAAGTAGCCGCA -3' (SEQ ID NO: 16)

Antisense strand 5'-TGCGGCTACTTTATTTCCATTTTGAGC -3' (SEQ ID: NO: 17)

L386F:

Sense strand 5'- CCGTATTAAGTTCGATCCAACTTATAGC -3' (SEQ ID NO: 18)

Antisense strand 5'- GCTATAAGTTGGATCGAACTTAATACGG -3' (SEQ ID:
NO: 19)

- 5 **Table 4:** Mutations with positive impact on thermo stability of s-GDH mutants already comprising other mutants for e.g. improving glucose specificity

Enzyme	% M/G at 30 mM sugar in	Stability, 30 min, 64 °C	Amino acid exchanges
WT	105 %	80 %	-
Mutant A	25 %	40 %	T348G
Mutant V	25 %	50 %	T348G +T313D
Mutant VI	25 %	45 %	T348G +N267Y
Mutant 6	1.5 %	5 %	N122K+L169F+Y171G+E245D+M341V+T348G+ins429P
Mutant 19	2 %	10 %	N122K+S124K+L169F+Y171G+E245D+M341V+T348G+ins429P
Mutant 21	2 %	15 %	N122K+S124K+L169F+Y171G+E245D+M341V+T348G+L386F+ins429P
Mutant 24	2 %	25 %	N122K+S124K+L169F+Y171G+E245D+M341V+T348G+L386F+ins429P
Mutant 22	2.5 %	20 %	N122K+S124K+L169F+Y171G+E245D+Q246H+M341V+T348G+L386F +ins429P
Mutant 25	2.5 %	55 %	N122K+S124K+L169F+Y171G+E245D+Q246H+M341V+T348G+L386F +ins429P
Mutant 29	2.5 %	75 %	D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+M341V+T348S+L386F+ins429P
Mutant 30	2.5 %	60 %	D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+G339T+M341V+T348G+L386F+ins429P
Mutant 31	3 %	80 %	D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+M341V+T348S+L386F+ins429P+V436P
Mutant 32	3.3 %	67 %	D87R+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+M341V+T348S+V349G+A354T+L386F+ins429P

Enzyme	% M/G at 30 mM sugar in	Stability, 30 min, 64 °C	Amino acid exchanges
Mutant 33	4.3 %	80 %	D87R+L110H+N122K+S124K+S146G+L169F+Y171G+E245D+Q246H+V298L+M341V+T348S+L386F+ins429P

The above results show that the amino acid exchanges D87R, N122K, S124K, S146A or G, preferably G, S146G, L187F or M; N267Y, V298L, T313D and L386F improve the thermo stability of the basic mutant 6.

- 5 The substitution D87R; N122K; S124K; S146G; V298L and L386F have quite strong effects on improvements in thermo stability.

Example 7

Generating mutants with high substrate specificity for glucose as compared to maltose and improvement of affinity towards glucose

- 10 In WO 02/34919 several amino acid exchanges at different positions of s-GDH have been identified and shown to enhance the substrate specificity for glucose as compared to e.g., maltose. Combinations of the amino acid exchange T348G with amino acid substitutions at other positions for example at positions 169, 171, 245, 341 and/or 349 enhanced the substrate specificity furthermore. Several different s-GDH mutants with improved specificity for glucose but as compared to maltose
15 but with rather a low affinity for the substrate glucose were selected and attempts made to improve their affinity for glucose.

- As is known from the experiments summarized in Tables 2 and 3 the amino acid substitutions L110H or Y; N229A, G or S; Q246H, M or N; Y333A; G339T; M341V; V349A or G and V436P appear appropriate to enhance the affinity of an s-GDH mutant for glucose. Strongest effects on affinity are seen with the mutants L110H, Q246H; G339T; M341V; V349G and V436P. Further strong improvements of affinity were found with the amino acid exchanges Q246H, M341V; V349G and V436P. Point mutations are introduced into already existing mutants by the same
20 strategy as already exemplified in Example 6, therefore here only the specific primers for the substitutions Q246H are given.

25 Sense stand 5'- GGTAATTATTGCAGTCTGATCATGGCCC -3' (SEQ ID NO: 20)

Antisense strand 5'- GGGCCATGATCAGACTGCAATAATTACC -3' (SEQ ID: NO: 21)

5 The determination of affinity to glucose via the screening Km-value measurement as described in Example 3 was performed. The apparent Km-value was calculated from the plots of different substrate concentration versus enzyme activity.

The specific activity was worked out as described in Example 8.

Combinations of exchanges identified as appropriate for improving substrate specificity, affinity and/or stability have been introduced into mutated s-GDH with starkly improved specificity for glucose as compared to maltose.

10 **Table 5: Combination of various amino acid substitutions in s-GDH mutants with improved substrate specificity for glucose as compared to maltose**

Enzymes	screening Km-value in %	app. Km-value mM Glucose	app. Km-value mM Maltose	M/G in %	Specific activity U/mg
WT	70	0,7	1,4	105	800
Mutant 6	8	64,7	714	1.5	268
Mut.13 (=Mutant 6 +Q246H)	20	17,1	208	3	430
Mutant G	12	11	110	2	351
Mut.J (=Mutant G + Q246H)	18	8	143	3	489
Mutant 22	18	11	n.d.	2.5	400
Mutant 23 (=mutant 22, + Q246N)	15	13	n.d.	2	350
Mutant 29 (like mutant 22, but T348S)	21	11	n.d.	2.5	400
Mutant 30 (= mutant 22 + G339T	26	9	n.d.	2.5	350
Mutant 31 (= mutant 29 + V436P)	33	6	n.d.	3	380
Mutant 32 (= mutant 29 + V349G + A354T)	32	n.d.	n.d.	3.3	220.
Mutant 33 (= mutant 29 + L110H)	28	n.d.	n.d.	4.3	350

It can be clearly seen that on all mutant types the additional amino acid exchange Q246H produced an enhancement of affinity towards glucose and an improvement concerning specific activity. Mutant 6 has the amino acid exchanges at position T348G, N122K, L169F, Y171G, E245D, M341V and an insertion of proline at position 429 as mutant 13 and additional Q246H. Mutant J has the amino acid exchanges at position T348G, Y171G, E245D, M341V, N428P as mutant G and additional Q246H.

Mutant 22 has the amino acid exchanges at position T348G, N122K, S124K, L169F, Y171G, E245D, Q246H, M341V, L386F and an insertion of proline at position 429. Mutant 29 has all the exchanges of mutant 22 except T348G, which is exchanged to T348S, and resulted in an improvement of velocity. Mutant 30 and 31 achieved even higher Km-values for glucose by exchanging additionally G339T and V436P.

Example 8

Purification of wild-type or variant s-GDH and analysis of enzymatic activity and specific activity, respectively

E. coli cells comprising an appropriate s-GDH expression vector are grown (4 x yeast-Amp. 37 °C), harvested and resuspended in potassium phosphate buffer pH 7.0. Cell disruption was performed by French Press passage (700-900 bar). After centrifugation the supernatant was applied to a S-Sepharose (Amersham Pharmacia Biotec) column equilibrated with 10 mM potassium phosphate buffer pH 7.0. After washing, the s-GDH was eluted using a salt gradient 0-1 M NaCl. The fractions showing s-GDH activity were pooled, dialyzed against potassium phosphate buffer pH 7.0 and re-chromatographed on re-equilibrated S-sepharose column. The active fractions were pooled and subjected to a gel filtration using a Superdex® 200 column (Amersham). The active fractions were pooled and after addition of CaCl₂ (3 mM end concentration) stored at -20 °C.

Protein determination was performed using the Protein Assay Reagent no. 23225 from Pierce (calibration curve with BSA, 30 Min. 37 °C).

For measurement of the enzyme activity the s-GDH samples were diluted to 1 mg protein/ml with 0.0556 mM pyrroloquinoline quinone (PQQ); 50 mM Hepes; 15 mM CaCl₂ pH 7.0 and incubated at 25 °C for 30 minutes for reconstitution or activation.

- 35 -

After activation, samples were diluted with 50 mM Hepes; 15 mM CaCl₂ pH 7.0 to approximately 0,02 U/ml, and 50 µl of each diluted sample was added to 1000 µl of a 0.2 M citrate buffer solution (pH 5.8; at 25 °C) containing 0.315 mg (4-(dimethylphosphinylmethyl)-2-methyl-pyrazolo-[1.5a]-imidazol-3-yl)-(4-nitro-sophenyl)-amine (see patent US 5,484,708)/ml as a mediator and 30 mM sugar.

Extinction at 620 nm is monitored during the first 5 minutes at 25 °C.

One Unit enzyme activity corresponds to the conversion of 1 mMol mediator/min under the above assay conditions

Calculation:

Volume Activity (U/ml) = (total volume * dE/min [U/ml]) : (ε * sample volume * 1)
(ε = coefficient of extinction; ε_{620 nm} = 30[1 * mmol⁻¹ * cm⁻¹]).

Specific Activity (U/mg) = Volume activity U/ml divided by protein concentration mg/ml results in U/mg

The assays were performed with glucose and maltose (Merck, Germany), respectively.

Results relating to enzyme activity as well as to specific activity have been included into the Tables given in the previous Examples.

Patent Claims

1. A mutant of PQQ-dependent soluble glucose dehydrogenase (s-GDH; EC 1.1.5.2) with improved specificity for glucose as compared to maltose, having a substitution of threonine at position 348 by either glycine, alanine or serine, wherein said mutant additionally comprises
- 5
- a) at least one mutation for improving the stability of the mutant,
- b) at least one mutation for improving the affinity of the mutant to glucose, and optionally
- c) one or more mutation(s) for further improving the specificity of the mutant for glucose as compared to maltose, and
- 10
- wherein these positions correspond to the amino acid positions known from the *A. calcoaceticus* s-GDH wild-type sequence (SEQ ID NO: 2).
- 15
2. The s-GDH mutant according to claim 1, wherein said mutation for improving the stability is an amino acid substitution selected from the group consisting of L110H, Q246H; G339T; M341V; V349G and V436P.
3. The s-GDH mutant according to claim 1, wherein said mutation for improving the the affinity to glucose is selected from the group consisting of L110H or Y; N229A, G or S; Q246H, M or N; Y333A; G339T; M341V; V349A or G and V436P.
- 20
4. The s-GDH mutant according to claim 1, wherein said mutation for improving the specificity of the mutant for glucose as compared to maltose is an amino acid substitution is an amino acid substitution selected from the group consisting of Q145P; D163G or N; Q164F; L169F; Y171G; I208L or V; T224I; E245D; G276S; A294D or E; V300A, S, N, Y or I; T307G; T323V; A354Y, E or L; R378I, M, A or D; N428P and insertion 429 P.
- 25
5. The s-GDH mutant according to claim 2, wherein said substitution for improving the stability is selected from the group consisting of is selected from the group consisting of D87R; N122K; S124K; S146G; V298L and L386F.
- 30
6. The s-GDH mutant according to claim 3, wherein said substitution for improving the the affinity to glucose is selected from the group consisting of

is selected from the group consisting of L110H, Q246H; G339T; M341V; V349G and V436P.

7. The s-GDH mutant according to claim 4, wherein said substitution for improving the specificity of the mutant for glucose as compared to maltose is selected from the group consisting of L169F; Y171G; E245D; N428P and insertion 429P.
8. An isolated polynucleotide encoding an s-GDH mutant protein according to any of claims 1 to 7.
9. An expression vector comprising an isolated polynucleotide as defined in claim 8 operably linked to a promoter sequence capable of promoting the expression of said polynucleotide in a host cell.
10. A host cell comprising the expression vector of claim 9.
11. A process for producing s-GDH mutants comprising culturing the host cell of claim 10 under conditions suitable for production of the enzyme mutants.
12. An expression vector comprising an isolated polynucleotide as defined in claim 11 operably linked to a promoter sequence capable of promoting its expression in a cell-free peptide synthesis system.
13. A process for producing s-GDH mutants with the construct of claim 12 in a cell-free peptide synthesis system under conditions suitable for production of the said enzyme mutants.
14. A method of detecting, determining or measuring glucose in a sample using a s-GDH mutant according to any of claims 1 to 7, said improvement comprising contacting the sample with said mutant.
15. The method of claim 14 further characterized in that said detection, determination or measurement of glucose is performed using a sensor or test strip device.
16. A device for the detection or measurement of glucose in a sample comprising a s-GDH mutant according to any of claims 1 to 7 and other reagents required for said measurement.

Fig. 1

Amino acid sequences of *A. calcoaceticus* (top) and
A. baumannii (bottom)

```

1 DVPLTPSQFAKAKSENFDDKKVILSNLNKPHALLWGPDNQIWLTERATGKI 50
|:|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
1 DIPLTPAQFAKAKTENFDDKKVILSNLNKPHALLWGPDNQIWLTERATGKI 50

51 LRVNPESGSKVTVFQVPEIVNDADGQNGLLGFAFHPDFKNNPYIYISGTF 100
||||| ||| |||||.|||||.|||||.|||||.|||||.|||||.|||||.
51 LRVNPVSGSAKTVFQVPEIVSDADGQNGLLGFAFHPDFKHNPIYIISGTF 100

101 KNPKSTDKELPNQTIIRRYTYNKSTDLEKPVDLLAGLPSSKDHQSGRLV 150
|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
101 KNPKSTDKELPNQTIIRRYTYNKTTDTFEKPIDLIAGLPSSKDHQSGRLV 150

151 IGPDQKIYYTIGDQGRNQLAYLFLPNQAQHTPTQQELNGKDYHTYMGKVL 200
|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
151 IGPDQKIYYTIGDQGRNQLAYLFLSNQAQHTPTQQELNSKDYHTYMGKVL 200

201 RLNLDSGSIKDNPSFNGVVSIIYTLGHRNPQGLAFTPNGKLLQSEQGPNS 250
|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
201 RLNLDSGSIKDNPSFNGVVSIIYTLGHRNPQGLAFAPNGKLLQSEQGPNS 250

251 DDEINLIVKGGNYGWPNAVAGYKDDSGYAYANYSAANKS.IKDLAQNGVK 299
|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
251 DDEINLVKGGNYGWPNAVAGYKDDSGYAYANYSAATNKSQIKDLAQNGIK 300

300 VAAGVPVTKESEWTGKNFVPPLKTLTYTVQDTYNYNDPTCGEMTYICWPTV 349
||| |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
301 VATGVPVTKESEWTGKNFVPPLKTLTYTVQDTYNYNDPTCGEMAYICWPTV 350

350 APSSAYVYKGGKKAITGWENTLLVPSLKRGVIFRIKLDPTYSTTYDDAVP 399
|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
351 APSSAYVYTGGKKAIPGWENTLLVPSLKRGVIFRIKLDPTYSTTLDDAIP 400

400 MFKSNNRYRDVIASPDGNVLYVLTDTAGNVQKDDGSVTNTLENPGSLIKF 449
|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.
401 MFKSNNRYRDVIASPEGNTLYVLTDTAGNVQKDDGSVTHLENPGSLIKF 450

450 TYKAK 454
|||
451 TYNGK 455

```


Fig. 2

Schematic diagram of the plasmide with gene for s-GDH (pACSGDH)




Fig. 3a

Sequence vector pACSGDH

```

cactaactga ttacgcaccg catgtaaccg ttttcaatct gtgagtaaatt tcacagttta 60
ttaacattgt gatagctatg atgacaacgt ttgtgcgact gtaactaacg tgtaacagtt 120
agttgtcagt tttgctgggg tatttcgctt ataaaaaccg ttatcacaat atccccgcgac 180
taccggacaa aaataaagag ttgaataaga gcttatccca ttagggctat tttacttgcc 240
atthttggacc tgggcagtg cgcgcaaaac gcggttagcgt tttgaacgcg ctagcggcgg 300
cccgaagggc gagcgtagcg agtcaaacct cacgtactac gtgtacgctc cgggtttttgc 360
gcgctgtccg tgtccaaact gctgcgcca taacgcctgg tgggataggc tctaaatacg 420
cttcggcggt cagtaacacg cgtaaacgtg ctgaacagcc gggcattttt ttacgctata 480
ccctacataa taaaaccgga gctaccatga ataagaagg actgaccctt tctgccgtga 540
tggcaagtct gttattcggc gcgcacgcgc atgcccgcga tgttcctcta actccatctc 600
aatttgctaa agcgaaatca gagaactttg acaagaaagt tattctatct aatctaaata 660
agccgcacgc gttgttatgg ggaccagata atcaaatthg gtttaactgag cgagcaacag 720
gtaagattct aagagttaat ccagagtcgg gtagtgtaaa aacagthttt caggtaccag 780
agattgtcaa tgatgctgat gggcagaatg gtttattagg ttttgccttc catcctgatt 840
ttaaaaataa tccttatatc tatatttcag gtacatttaa aaatccgaaa tctacagata 900
aagaattacc gaaccaaacg attattcgtc gttataccta taataaatca acagatacgc 960
tcgagaagcc agtcgattta ttagcaggat taccttcac aaagaccat cagtcagggtc 1020
gtcttgctcat tgggccagat caaaagattt attatacgat tggtgaccaa gggcgtaacc 1080
agcttgctta tttgttcttg ccaaatcaag cacaacatac gccaactcaa caagaactga 1140
atggtaaaga ctatcacacc tatatgggta aagtactacg cttaaatctt gatggaagta 1200
ttccaaagga taatccaagt tttaacgggg tggttagcca tatttataca cttggacatc 1260
gtaatccgca gggcttagca ttcactccaa atgggtaaatt attgcagtct gaacaaggcc 1320
caaactctga cgatgaaatt aacctcattg tcaaagggtg caattatggt tggccgaatg 1380
tagcaggtta taaagatgat agtggtatg cttatgcaaa ttattcagca gcagccaata 1440
agtcaattaa ggatttagct caaaatggag taaaagtagc cgcaggggtc cctgtgacga 1500
aagaatctga atggactggg aaaaactthg tcccaccatt aaaaacttha tataccgttc 1560
aagataccta caactataac gatccaactt gtggagagat gacctacatt tgctggccaa 1620
cagttgcacc gtcactctgc tatgtctata agggcggtaa aaaagcaatt actggttggtg 1680
aaaatacatt attggttcca tctttaaacc gtggtgtcat tttccgtatt aagttagatc 1740
caacttatag cactacttat gatgacgctg taccgatgtt taagagcaac aaccgttatc 1800
gtgatgtgat tgcaagtcca gatgggaatg tcttatatgt attaaactgat actgccggaa 1860
atgtccaaaa agatgatggc tcagtaacaa atacattaga aaaccagga tctctcatta 1920
agttcaccta taaggctaag taatacagtc gcattaaaaa accgatctat aaagatcggg 1980
tttttttagt ttagaaaaga attcactggc cgctgtthta caacgtcgtg actgggaaaa 2040
ccctggcggt acccaactta atcgccctgc agcacatccc ctttcgcca gctggcgtaa 2100
tagcgaagag gcccgaccg atcgcccttc ccaacagttg cgcagcctga atggcgaatg 2160
gcgcctgatg cggtatthtc tccttacgca tctgtgcggg atttcacacc gcatatgggtg 2220
cactctcagt acaatctgct ctgatgccc atagttaagc cagccccgac acccgccaac 2280
acccgctgac gcgcccctgac gggcttgtct gctcccggca tccgcttaca gacaagctgt 2340
gaccgtctcc gggagctgca tgtgtcagag gttttcacg tcatcaccga aacgcgcgag 2400
acgaaagggc ctcgtgatac gcctatthtt ataggttaat gtcatgataa taatggthtt 2460
ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga acccctattt gtttattthtt 2520
ctaaatacat tcaaatatgt atccgctcat gagacaataa ccctgataaa tgcttcaata 2580
atattgaaaa aggaagagta tgagtattca acatttccgt gtcgcctta tccctthtt 2640
tgccgcatth tgcttctctg tttttgctca ccagaaacg ctggtgaaag taaaagatgc 2700
tgaagatcag ttgggtgcac gagtgggtta catcgaaactg gatctcaaca gcggtaaagat 2760
ccttgagagt tttcgcccc aagaacgtht tccaatgatg agcactthta aagttctgct 2820
atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca 2880

```

Fig. 3b

```

ctattctcag aatgacttgg ttgagtactc accagtcaca gaaaagcatc ttacggatgg 2940
catgacagta agagaattat gcagtgctgc cataaccatg agtgataaca ctgcggccaa 3000
cttacttctg acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg 3060
ggatcatgta actcgccttg atcgttggga accggagctg aatgaagcca taccaaacga 3120
cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg 3180
cgaactactt actctagctt cccggcaaca attaatagac tggatggagg cggataaagt 3240
tgcaggacca cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg 3300
agccggtgag cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc 3360
ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca 3420
gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc 3480
atatatactt tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat 3540
cctttttgat aatctcatga ccaaaatccc ttaacgtgag ttttcgcttc actgagcgtc 3600
agaccccgta gaaaagatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg 3660
ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt tgtttgccgg atcaagagct 3720
accaactctt tttccgaagg taactggctt cagcagagcg cagataccaa atactgtcct 3780
tctagtgtag ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct 3840
cgctctgcta atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg 3900
gttggactca agacgatagt taccggataa ggccgagcgg tcgggctgaa cgggggggttc 3960
gtgcacacag cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga 4020
gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg gacaggatc cggtaagcgg 4080
cagggtcgga acaggagagc gcacgagggg gcttccaggg ggaaacgcct ggtatcttta 4140
tagtcctgtc ggggttctgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg 4200
ggggcgagc ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg 4260
ctggcctttt gctcacatgt tctttcctgc gttatcccct gattctgtgg ataaccgtat 4320
taccgccttt gagtgaactg ataccgctcg ccgcagccga acgacggggc ccg 4373

```

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/003207

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N9/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, EMBASE, BIOSIS, FSTA, Sequence Search, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/008132 A (ROCHE DIAGNOSTICS GMBH; F. HOFFMANN-LA ROCHE AG; BOENITZ-DULAT, MARA;) 26 January 2006 (2006-01-26) page 15, line 29 - page 16, line 3 page 17, line 31 - page 21, line 28 -----	1-4, 6-16
X	US 2003/104595 A1 (KRATZCH PETER ET AL) 5 June 2003 (2003-06-05) paragraph [0069] paragraph [0077] - paragraph [0097] -----	1, 4, 7-16
X	WO 02/34919 A (ROCHE DIAGNOSTICS GMBH; F. HOFFMANN-LA ROCHE AG) 2 May 2002 (2002-05-02) page 14, line 4 - line 25 page 16, line 25 - page 20, line 28 ----- -/-	1, 3, 4, 7-16

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 July 2007

Date of mailing of the international search report

06/08/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Strobel, Andreas

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/003207

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>IGARASHI S ET AL: "Molecular engineering of PQQGDH and its applications" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 428, no. 1, 1 August 2004 (2004-08-01), pages 52-63, XP004517987 ISSN: 0003-9861 the whole document</p>	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/003207

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006008132	A	26-01-2006	
		AU 2005263591 A1	26-01-2006
		CA 2570593 A1	26-01-2006
		CN 1989241 A	27-06-2007
US 2003104595	A1	05-06-2003	
		AU 1596602 A	06-05-2002
		BR 0114962 A	28-10-2003
		CA 2427029 A1	02-05-2002
		CN 1578836 A	09-02-2005
		WO 0234919 A1	02-05-2002
		EP 1332216 A1	06-08-2003
		JP 3845618 B2	15-11-2006
		JP 2004512047 T	22-04-2004
		JP 3889434 B2	07-03-2007
		JP 2006314322 A	24-11-2006
		PL 362548 A1	02-11-2004
		US 2006148056 A1	06-07-2006
		US 2004005683 A1	08-01-2004
WO 0234919	A	02-05-2002	
		AU 1596602 A	06-05-2002
		BR 0114962 A	28-10-2003
		CA 2427029 A1	02-05-2002
		CN 1578836 A	09-02-2005
		EP 1332216 A1	06-08-2003
		JP 3845618 B2	15-11-2006
		JP 2004512047 T	22-04-2004
		JP 3889434 B2	07-03-2007
		JP 2006314322 A	24-11-2006
		PL 362548 A1	02-11-2004
		US 2003104595 A1	05-06-2003
		US 2006148056 A1	06-07-2006
		US 2004005683 A1	08-01-2004